Topical Use of Difinsa53™ to Prevent Radiation Dermatitis
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Phase II trial of the silibin containing cream, Difinsa53 to determine efficacy in delaying,
ameliorating, or preventing radiation dermatitis in patients with breast cancer undergoing
whole breast radiation.